NO ODOR PRODUCTS, LLC – Trademark Portfolio
Entity Type: 16
NO ODOR PRODUCTS, LLC holds 8 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 5 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 3 Nice Classification classes. Currently, 8 trademarks are registered. Notable registered marks include NO ODOR, ODOREZE, AMMOSORB, SCENTOUT, and SMELLEZE. The owner is based in TEMPE, AZ.
1450 WEST 12TH PLACE
TEMPE, AZ 85281
Showing of trademarks Trademarks
Trademark Classifications
NO ODOR PRODUCTS, LLC's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Games and playthings; gymnastic and sporting articles; decorations for Christmas trees
Frequently Asked Questions
How many trademarks does NO ODOR PRODUCTS, LLC have?
NO ODOR PRODUCTS, LLC has 8 U.S. trademarks filed with the USPTO. Of these, 8 registered.
What trademark classes does NO ODOR PRODUCTS, LLC file in?
NO ODOR PRODUCTS, LLC files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 1 (Chemicals), Class 28 (Toys & Sporting Goods). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are NO ODOR PRODUCTS, LLC's most well-known trademarks?
NO ODOR PRODUCTS, LLC's registered trademark portfolio includes well-known marks such as NO ODOR, ODOREZE, AMMOSORB, SCENTOUT, and SMELLEZE. These are among 8 currently registered trademarks in the portfolio.
What is NO ODOR PRODUCTS, LLC's trademark registration success rate?
NO ODOR PRODUCTS, LLC has a 100% trademark registration rate, with 8 out of 8 resolved applications resulting in successful registration. Currently, 0 applications are pending review.